IL33 and chronic obstructive pulmonary disease: Although the predictive efficiency of serum IL-33 for AE risk is relatively low, its high sensitivity suggests that IL-33 could potentially become a key biomarker and therapeutic target for COPD, pending further confirmation through additional studies.